Metastatic renal cell carcinoma
Development and Regulatory status
Trial or other data
Jun 18: Argos Therapeutics terminates a PII trial due to lack of efficacy (NCT01482949) .
Apr 18: Argos Therapeutics discontinues the PIII ADAPT trial based on an interim analysis in which rocapuldencel-T in combination with sunitinib failed to achieve its four co-primary end points which were focused on various measures of survival .